Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl Sulfate
2. Etx2514
3. Sulfuric Acid, Mono((2s,5r)-2-(aminocarbonyl)-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl) Ester
1. Durlobactam [inn]
2. Durlobactam [usan]
3. Psa33ko9wa
4. 1467829-71-5
5. Ext2514
6. [(2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] Hydrogen Sulfate
7. Sulfuric Acid, Mono((2s,5r)-2-(aminocarbonyl)-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl) Ester
8. Unii-psa33ko9wa
9. Durlobactam (usan/inn)
10. Durlobactam [usan:inn]
11. Chembl4298137
12. Schembl15319894
13. Who 10824
14. Zinc220881117
15. D11591
16. (2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl Sulfate
17. (2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl Hydrogen Sulfate
| Molecular Weight | 277.26 g/mol |
|---|---|
| Molecular Formula | C8H11N3O6S |
| XLogP3 | -2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 277.03685625 g/mol |
| Monoisotopic Mass | 277.03685625 g/mol |
| Topological Polar Surface Area | 139 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 536 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
beta-Lactamase Inhibitors
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Durlobactam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Durlobactam, including repackagers and relabelers. The FDA regulates Durlobactam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Durlobactam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Durlobactam supplier is an individual or a company that provides Durlobactam active pharmaceutical ingredient (API) or Durlobactam finished formulations upon request. The Durlobactam suppliers may include Durlobactam API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Durlobactam as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Durlobactam API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Durlobactam as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Durlobactam and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Durlobactam NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Durlobactam suppliers with NDC on PharmaCompass.
Durlobactam Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Durlobactam GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Durlobactam GMP manufacturer or Durlobactam GMP API supplier for your needs.
A Durlobactam CoA (Certificate of Analysis) is a formal document that attests to Durlobactam's compliance with Durlobactam specifications and serves as a tool for batch-level quality control.
Durlobactam CoA mostly includes findings from lab analyses of a specific batch. For each Durlobactam CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Durlobactam may be tested according to a variety of international standards, such as European Pharmacopoeia (Durlobactam EP), Durlobactam JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Durlobactam USP).
LOOKING FOR A SUPPLIER?
